Haploidentical hematopoietic SCT (haplo-HSCT) is to be established in patients with acquired severe aplastic anemia (SAA) refractory to immunosuppressive therapy and lacking HLA-matched related or unrelated donors. Graft failure (GF) and GVHD have been major obstacles to HSCT. A total of 17 children and adolescents with SAA underwent haplo-HSCT in our center. The conditioning regimen consisted of BU, fludarabine, CY and anti-thymocyte globulin. All patients received cyclosporine, short-term MTX, mycophenolate mofetil and basiliximab for GVHD prophylaxis. Mesenchymal stem cells derived from unrelated umbilical cord were infused on day 1. Neutrophil engraftment was achieved in all 17 patients in a median time of 16 days (range 9-25 days). The median time of platelet engraftment was 22 days (range 9-95 days) in 16 patients. The cumulative incidence (CI) of II-IV acute GVHD (aGVHD) at day +100 was 30.53 ± 11.12% and III-IV aGVHD occurred in only one patient. The CI of chronic GVHD was 21.25 ± 13.31%. Secondary GF with autologous hematopoiesis recovery occurred in one patient. The OS was 71.60 ± 17.00% at a median follow-up of 362 (36-1321) days. These limited promising data suggest that haplo-HSCT is feasible as a salvage therapy for children and adolescents with refractory SAA who lack matched donors.
INTRODUCTION
Although allogeneic hematopoietic SCT (allo-HSCT) from HLAidentical sibling donors is the first-line treatment of choice for young patients with acquired severe aplastic anemia (SAA), many patients lack HLA-identical sibling donors, particularly as family size is shrinking in China. Immunosuppressive therapy (IST) is the most commonly used initial modality for SAA. Despite the great advances brought about by the use of antithymocyte globulin (ATG) in SAA, approximately one-third of the cases are expected not to respond after initial therapy with horse ATG. 1 The optimal treatment for these patients has not been established. Allo-HSCT from HLA-matched unrelated donors is the choice of therapy for these patients. Although dramatic improvement in survival after HLA-matched HSCT has occurred in the past decade, 30-50% patients lack matched and available donors. Haploidentical HSCT has been successfully used in the management of hematological malignancies, with comparable disease-free survival and acceptable transplant-related mortalities (TRMs). 2 Haploidentical transplants have been carried out in patients with SAA failing IST and lacking HLA-matched related or unrelated donors. But the outcomes of haploidentical HSCT in SAA were not consistent for the small cohorts and different conditioning regimens and GVHD prophylaxis regimens. The probability of graft failure (GF) at 100 days was 25% and the OS at 5 years was 30% in 20 patients as reported by the Center for International Blood and Marrow Transplant Research (CIBMTR) SAA Working Party, 3 while all 19 patients achieved donor myeloid engraftment and the OS was 64% in the Xu et al. report. 4 Successful unmanipulated SCT from haploidentical 3-loci-mismatched parents in two children with SAA was performed in our preliminary clinical trial. 5 In this report, we describe the favorable outcome of another cohort of consecutive 17 children and adolescents with SAA who underwent haploidentical HSCT in our center.
PATIENTS AND METHODS

Patients' characteristics
From March 2010 to April 2013, consecutive 17 children and adolescents with acquired SAA received haploidentical HSCT in our center. The inclusion criteria were (1) having acquired SAA at age o20 years, as defined by the International Aplastic Anemia Study Group; 6 (2) being refractory to IST, including CsA or ATG or secondary GF; (3) having a lack of HLA-identical sibling or unrelated donors; (4) absence of active infection and free of significant deficits in vital organs. The protocol was approved by the general hospital of the Air Force Review Board of The People Liberation Army. All patients underwent haploidentical HSCT after obtaining written informed consent from their guardians. The selection of donors was based on the compatibility of HLA molecular typing for HLA-A, B and DRB1 by high-resolution techniques. Other factors included their blood group, gender and age.
prophylaxis. Basiliximab was given at 20 mg/day on days 1 and +4. The dosage of CsA was 2.5 mg/kg/day i.v. from day − 10, which was switched to oral CsA once gut function was normal and then tapered from day +90 if no GVHD occurred. MTX was administered at a dose of 15 mg/m 2 i.v. on day +1 and 10 mg/m 2 i.v. on days +3, +6 and +11. MMF (0.25 and 0.5 g for children and adolescents, orally bi-day, respectively) was administered from day +7 to day +90. In addition, mesenchymal stem cells (MSCs) derived from unrelated umbilical cord were cultured as previously described and infused on day 1. 7 Donors received 5 μg/kg/day granulocyte-colony stimulating factor (G-CSF) for 5 consecutive days. BM was collected on day 1 and PBSCs were harvested on day 2. All patients received a combination of BM and PBSCs. All patients were hospitalized in rooms with high-efficiency particle-arresting air filters, and received antibiotic prophylaxis with oral trimethoprimsulfamethoxazole, fluconazole and acyclovir. Recipients received 5 μg/kg/day G-CSF from day +7 until neutrophil engraftment. Patients with CMV antigenemia monitoring by real-time PCR were offered pre-emptive treatment with ganciclovir or foscarnet.
Assessment of engraftment and toxicities
Neutrophil engraftment was defined as the first day of an ANC ⩾ 0.5 × 10 9 /L for 3 consecutive days, and platelet recovery was defined as the first day of a platelet count ⩾ 20 × 10 9 /L for 7 days without platelet transfusion. Hematopoietic chimerism was confirmed by chromosomal FISH for sexmismatched pairs and DNA fingerprinting of short tandem repeats' (STR) PCR amplification for sex-matched pairs. The BM was examined at +1, +2, +3, +6 months and 1 year after transplantation.
Diagnosis of acute GVHD (aGVHD) and chronic GVHD (cGVHD) was based on standard clinical criteria 8, 9 . Secondary GF was defined as the absence of donor cells in the BM after initial engraftment. The regimenrelated toxicity was evaluated according to Seattle Toxicity Criteria. 10 
Statistics
Analysis was performed on 10 November 2013, with a median follow-up time of 362 (range 36-1321) days. Cumulative incidence curves were used in a competing risks setting, with death being treated as a competing event to calculate the probabilities of aGVHD. OS was analyzed using the Kaplan-Meier method. The statistical software packages (SPSS 16.0 (SPSS Inc., Chicago, IL, USA) and SAS (SAS, Cary, NC, USA)) were used for all statistical analyses.
RESULTS
Patients' characteristics
The patients' characteristics are summarized in Table 1 . A total of 17 patients were enrolled in this study. The median age was 10 years, including 14 children and 3 adolescents. Five cases had failed to respond to one course of ATG and 11 patients were refractory to other IST treatment. One child underwent unrelated HSCT before haploidentical HSCT. There are three reasons why 11 patients were only treated with CSA pre-HSCT. First, only rabbit ATG is available in China, which is much less effective than horse ATG. The cost of one course of ATG is~$40 000 and the response rates varied widely in different hospitals, ranging from 40 to 80%. If the patients failed with the use of rabbit ATG, their guardians were not able to pay the cost of HSCT (~$60 000) again. Second, most of these patients suffered from life-threatening infection (6 patients) or refractory platelet transfusion (4 patients) for a long duration of pancytopenia. Hence HSCT was preferred for these patients. Third, the staff in our centers were skilled in haploidentical HSCT, because the haploidentical protocol was used to treat hematological malignancies since 1999. So we performed the investigational study on these SAA patients.
Regimen-related toxicity Grade III-IV regimen-related toxicity occurred in 3 (17.6%) patients. In the three cases with septicemia, two cases were well controlled but one case died of infection. Upper gastrointestinal hemorrhage occurred in one patient. Hepatitis associated with drugs occurred in three patients. Only one case developed grade I hemorrhagic cystitis although high-dose CY was used. No patient experienced veno-occlusive disease. The toxicities are shown in Table 2 .
Engraftment
The median infused total nucleated cell (TNC), CD34+, CD3+ and MSC count was 11.20 ×10 8 /kg (range 6.17-24.10), 6 .42 × 10 6 /kg Table 3 . Neutrophil engraftment was achieved in all 17 (100%) patients, the median time was 16 days (range 9-25 days). The median time of platelet engraftment was 22 days (range 9-95 days) in 16 (94.1%) patients. One patient who died of infection on day +36 did not achieve platelet engraftment. Full donor chimerism was confirmed in 7 patients by FISH and in 10 patients by STR at +1 month after transplantation and stable donor chimerism was detected in the following months except in one patient. The chimerism analysis was performed at +12 months in 8 patients who survived more than 1 year after HSCT. Full donor chimerism was found in 7 patients and full host chimerism was detected in one patient with secondary GF in +9 months after transplantation. He is alive and well with autologous hematopoietic recovery in +12 months.
GVHD
Acute GVHD was recorded in 13 (76.5%) patients. Among them, 8 cases (47.1%) had grade I aGVHD, 4 cases (23.5%) had grade II aGVHD and only 1 case (5.8%) died of grade III-IV skin and gut aGVHD at day +44 (Table 4) . Acute GVHD improved in all but one patient after treatment with methylprednisolone at a dose of 1-2 mg/kg per day and CsA or FK506. The gastrointestinal tract was affected by acute GVHD in four cases; all of them received additional basiliximab treatment. The cumulative incidence of II-IV aGVHD at day +100 was 30.53 ± 11.12%. Of the 15 patients who survived for more than 100 days after transplantation, 4 (26.7%) cases developed cGVHD. All were limited skin or hepatic cGVHD cases that were well controlled by CsA and glucocorticoids. The Karnofsky scores in these 4 patients were 80-90 and in the other 10 patients without cGVHD was 100. The cumulative incidence of cGVHD was 21.25 ± 13.31%.
The median time of discontinuation of the IST was 8 months (range 6-23 months).
Infection, TRM and OS CMV infection developed in 14 (82.3%) patients but no CMV disease occurred after pre-emptive therapy. No PTLD developed although EBV infection occurred in 7 (41.2%) patients with no antiviral agents used. Late-onset hemorrhagic cystitis for BK virus infection was seen in two patients. Pneumocystis carinii pneumonia developed in one patient on day +126. Three patients died of TRM and the causes of TRM were infection (n = 1) on day +36, severe aGVHD (n = 1) on day +44 and viral interstitial pneumonia (n = 1) on day +634.
Interestingly, 4 survived in 6 patients who previously received ATG or HSCT. A total of 14 patients have survived with an OS rate of 71.60 ± 17.00% (Figure 1 ) at a median follow-up of 362 (36-1321) days.
DISCUSSION
Age is a significant prognostic factor in HSCT. Data from the CIBMTR showed that the rates of GVHD and TRM were significantly lower in young patients compared with older adults with SAA and survival was inversely correlated with age in matched sibling donor HSCT setting. The 5-year OS was 82% and 50% for those o20 years of age and those 440, respectively. 11 Children with hematological disorders had lower rates of TRM and trends towards better LFS and OS following ex vivo T-cell depletion haplo-HSCT in CIBMTR data. 12 Therefore children and adolescents with SAA were enrolled in our study.
Many patients with SAA died from infection and bleeding for a long duration of pancytopenia. Recently, haplo-HSCT has emerged as a novel strategy for patients with SAA refractory to IST and lacking matched donors. But high GF and high GVHD remain the main challenges. Multiple transfusions before HSCT sensitize SAA patients with allo-Ags and increase the risk of GF besides HLA barrier in haplo-HSCT. Data from Seattle showed that none of the patients with mismatched related donors achieved long-term survival for high graft rejection and GVHD conditioning with CY/ ATG. 13 The conditioning regimen consisted of CY, and various doses of TBI decreased the incidence of GF and increased survival. Although the incidence of GF was 14% in 16 patients who underwent haplo-HSCT after conditioning with Cy/TBI (200 cGy/ day * 6 days), high incidence of grade II-IV aGVHD (78%) was reported by Wagner et al. 13 Tzeng et al. described that engraftment was found in all six patients receiving haplo-HSCT conditioning with CY and TBI 800 cGy. Infection and GVHD remained major problems, while the optimal dose of TBI was unknown. 14 In our conditioning regimen, fludarabine and low doses of BU were used to facilitate donor engraftment in addition to CY/ATG. Fludarabine inhibits or eradicates recipient's T cells, and then enhances engraftment. In a HLA-matched sibling setting, the incidence of GF reduced to 0% with fludarabine-based conditioning compared to 11% with standard CY/ATG regimen. The OS was also better. 15 In a phase II prospective study, no GF was found in 28 patients with SAA who received Flu/CY/ATG conditioning regimen. 16 BU is an alkylating agent with low immunosuppressive activity. The rejection rate was 22% in all 81 patients with acceptable toxicity conditioning with low doses of BU (4 mg/kg)/ CY and the OS was 56% at 8 years in HLA-identical sibling HSCT. 17 To enhance engraftment, BU at the dose of 8 mg/kg was used in our and Xu et al.'s 4 conditioning regimens. No additional toxicity directly associated with BU was found. All patients with heavy transfusion received two or three loci mismatched haplo-identical HSCTs with a conditioning regimen of Flu, BU and CY/ATG in our study. All patients achieved primary myeloid engraftment, while 1 case experienced secondary GF and one case died of infection for regimen-related toxicity. The high engraftment rate with acceptable regimen-related toxicities suggested this conditioning regimen as feasible before haplo-identical HSCT for SAA.
All patients received a combination of BM and peripheral blood HSCs. The double sources of stem cells were used for the following reasons. (1) Previous clinical data have shown that the incidence of GVHD was lower in patients who received G-CSF-primed BM than in patients who received PBSCs in HLA-matched sibling transplantation. 18 The incidence of aGVHD was only 6.3% in G-BM transplants compared with 33% in steady-state marrow transplants. 19 (2) Mixtures of G-PB and G-BM have successfully introduced T-cell hyporesponsiveness, polarization of T cells from Th1 to Th2 and protected from aGVHD. 20 (4) Higher-dose stem cell numbers may be given via a combination of G-BM and G-PBSC than via BM or PB alone to overcome the harmful effect of ATG on hematopoiesis.
2 (5) G-BM also may add BM-derived MSCs to grafts, which may reduce severe GVHD and enhance engraftment. 21 Except for GF, GVHD is the only negative complication of patients with SAA following HSCT because no graft-versus tumor effect is needed. The optimal HSCT protocol for SAA is aimed at reducing GVHD while maintaining stable donor engraftment. Basliximab is a potent immunosuppressant of IL-2-induced T-cell activation and proliferation. A significant reduction in the incidence of grade II-IV aGVHD from 33 to 11% was recorded in our center when adding basliximab to CsA, MTX and MMF after haploidentical HSCT for hematological malignancies. 22 Another study from Fang et al. 23 indicated that basliximab prevents GVHD efficiently following unrelated PBSCT. The incidence of grade III-IV aGVHD and cGVHD was 15.9 and 38.7%, respectively. 23 MSCs, a heterogeneous population of stromal cells, exert immunosuppressive effects via direct suppression of T lymphocytes or by secreting soluble cytokines to protect from GVHD. Cotransplantation of MSCs prevented life-threatening aGVHD in 13 children following allogeneic cord blood transplantation. The incidence of grade III-IV aGVHD was 0% in the MSC group versus 26% in the historic group. 24 In a mismatched unrelated transplantation setting, Baron reported that the proportion of patients with severe aGVHD was lower in MSC co-transplantation and the 1-year probability of dying from GVHD or infection while on treatment for GVHD was significantly lower than control (10% versus 31%). 25 Basliximab and MSCs were used in all our patients to further reduce GVHD incidence besides CsA, MTX and MMF. Although the overall incidence of aGVHD was high, most were well controlled and the severity is mild-moderate because only 1 case died of grade III-IV aGVHD. This indicates that a combination of basliximab,MSCs and CsA +MTX+MMF might be powerful as the GVHD prophylaxis.
In conclusion, our limited but promising data suggest that haploidentical HSCT may be feasible as a salvage therapy for children and adolescents with refractory acquired SAA who lack matched donors. Further prospective and randomized studies in large cohorts are needed to establish the rationale of haplo-HSCT as a salvage therapy for young SAA patients lacking matched donors.
